留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

真核延长因子eEF1A功能研究进展

程君 芮耀诚

程君, 芮耀诚. 真核延长因子eEF1A功能研究进展[J]. 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
引用本文: 程君, 芮耀诚. 真核延长因子eEF1A功能研究进展[J]. 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
CHENG Jun, RUI Yao-cheng. Advance in function of the eukaryotic elongation factor eEF1A[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
Citation: CHENG Jun, RUI Yao-cheng. Advance in function of the eukaryotic elongation factor eEF1A[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003

真核延长因子eEF1A功能研究进展

doi: 10.3969/j.issn.1006-0111.2012.02.003

Advance in function of the eukaryotic elongation factor eEF1A

  • 摘要: 真核延长因子(eEFs)是一类在蛋白质合成过程中发挥肽链延伸作用的重要分子,在真核生物体内它有eEF1和eEF2两个亚型。其中在肽链延伸过程中起主要作用的eEF1A 是eEF1的一个亚型,它不但能促进氨酰基-tRNA(aa-tRNA)与核糖体的A位点结合,发挥肽链延伸功能;而且近年来大量的研究表明它在细胞凋亡、肿瘤的发生、细胞内信号转导及心血管系统的调节方面均发挥了重要作用,而且这些作用与它在蛋白合成中的功能无关;这表明eEF1A是一个多功能蛋白,能够成为一个潜在的疾病防治的靶点。本文就国内外近几年来有关eEF1A的研究做一综述,介绍真核延长因子eEF1A功能研究的进展。
  • [1] Lamberti A,araglia M,longo O,et al.The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis[J]. Amino Acids,2004,26(4):443.
    [2] Infante C,sensio E,aavate JP,et al. Molecular characterization and expression analysis of five different elongation factor 1 alpha genes in the flatfish Senegalese sole (Solea senegalensis Kaup): Differential gene expression and thyroid hormones dependence during metamorphosis[J]. BMC Mol Biol,2008,9:19.
    [3] Maria K,Mateyak,Kinzy TG. eEF1A: Thinking outside the ribosome[J]. J Biol Chem,2010,5(4):432.
    [4] Ejiri Shin ichiro. Moonlighting functions of polypeptide elongation factor 1:from actin bundling to zinc finger protein r1-associated nuclear localization[J]. Biotechnol Biochem,2002,66(1):1.
    [5] Khalyfa A,Bourbeau D,Chen E,et al. Characterization of Elongation Factor-1A (eEF1A-1) and eEF1A-2/S1 Protein Expression in Normal and wasted Mice[J]. J Biol Chem,2001,276(25):22915.
    [6] Newbery HJ,Loh DH,Donoghue JE,et al. Translation elongation factor eEF1A2 is essential for post-weaning survival in mice[J]. J Biol Chem,2007,282(39):28951.
    [7] Pan J,Ruest LB,Xu SY,et al. Immuno-characterization of the switch of peptide elongation factors eEF1A-1/EF-1a and eEF1A-2/S1 in the central nervous system during mouse development[J]. Dev Brain Res,2004,149:1.
    [8] Andersen GR,Nissen P,Nyborg J. Elongation factors in protein biosynthesis[J]. Trends Biochem Sci,2003,28(8):434.
    [9] Villa E,Sengupta J,Trabuco LG,et al. Ribosome-induced changes in elongation factor Tu conformation control GTP hydrolysis[J]. Proc Natl Acad Sci,2009,106(4):1063.
    [10] Ruest LB,Marcotte R,Wang E. Peptide elongation factor eEF1A-2/S1 expression in cultured differentiated myotubes and its protective effect against caspase3-mediated apoptosis[J]. J Biol Chem,2002,277(7):5418.
    [11] Borradaile NM, Buhman KK, Listenberger LL, et al. A critical role for eukaryotic elongation factor 1A1 in lipotoxic cell death[J]. Mol Biol Cell,2006,17:770.
    [12] Talapatra1 S,Wagner J,Thompson CB. Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis[J]. Cell Death and Differ, 2002,9:856.
    [13] Li HT,Su YP,Cheng TM,et al. The interaction between interferon-induced protein with tetratricopeptide repeats-1 and eukaryotic elongation factor-1A[J]. Mol Cell Biochem,2010, 337:101.
    [14] Mansillaa F,Hansenb LL,Jakobsena H,et al. Deconstructing PTI-1: PT1-1 is a truncated, but not mutated form of translation elongation factor 1A1, eEF1A1[J]. Biochim Biophys Acta,2005,1727(2):116.
    [15] Zhang JP,Guo HT,Mi ZY,et al. EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells[J]. Exp Cell Res,2009,315:304.
    [16] Anand N,Urthy S,Mann G,et al.Protein elongation factor eEF1A2 is a putative oncogene in ovarian cancer[J]. Nat Genet,2002,31:301.
    [17] Tomlinson VA,ewbery HJ,ray NR,et al. Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours[J]. BMC cancer,2005,5:113.
    [18] Morikawa E,Moskowitz M,Huang Z,et al. L-Arginine infusion promotes nitric oxide dependent vasodilation,increases regional blood flow and reduces infarct volume in the rat[J]. Stroke,1994,25(2):429.
    [19] Yan GJ,You B,Chen SP,et al. Tumor necrosis factor-a downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1A1[J]. Circ Res,2008,103(12):591.
    [20] Picchi A,Gao X,Belmadani S. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome[J]. Circ Res,2006,99:69.
    [21] Agnoletti L,Curello S,Bachetti T,et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic:role of tumor necrosis factor-alpha[J]. Circulation, 1999,100:1983.
    [22] Gross SR,Kinzy TG. Tranlation elongation factor 1A is essential for regulation of actin cytoskeleton and cell morphology[J]. Nat Struct Mol Boil,2005,12:772.
    [23] Leclercq TM, Moretti PAB, Vadas MA, et al.Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity[J]. J Biol Chem,2008,283:9606.
    [24] Gillardon F. Interaction of elongation factor 1-a with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro[J]. Neuroscience,2009,163:533.
    [25] Yuka Hotokezaka,Udo Tobben,Hitoshi Hotokezaka,et al. Interaction of the Eukaryotic Elongation Factor 1A with NewlySynthesized Polypeptides[J]. J Biol Chem,2002,277(21):18545.
    [26] Shamovsky Iiya,Ivannikov Maxim,Kandel ES,et al. RNA-mediated response to heart shock in mammalian cells[J]. Nature,2006,440(23):556.
  • [1] 田硕, 厉建中.  转录因子ZNF24在肿瘤中的研究进展 . 药学实践与服务, 2023, 41(12): 710-713, 721. doi: 10.12206/j.issn.2097-2024.202204043
    [2] 张冬梅, 高迎春, 何蕾, 陈克明, 李文斌, 王荣, 马慧萍.  PC12细胞SLC6A4基因沉默稳转细胞系的建立及SLC6A4基因沉默对缺氧PC12细胞凋亡的影响 . 药学实践与服务, 2022, 40(5): 389-394, 463. doi: 10.12206/j.issn.2097-2024.202205093
    [3] 丁佳宁, 马进原, 朱全刚.  长链非编码RNA人母系表达基因3在肿瘤发生中作用的研究进展 . 药学实践与服务, 2019, 37(5): 390-393,421. doi: 10.3969/j.issn.1006-0111.2019.05.002
    [4] 唐杰, 林厚文, 孙凡.  海绵来源的smenospongine诱导乳腺癌MCF7细胞凋亡机制研究 . 药学实践与服务, 2018, 36(5): 399-402,421. doi: 10.3969/j.issn.1006-0111.2018.05.004
    [5] 王筱婧, 王东兴, 范洁, 高越, 张海.  泽漆抑制三阴乳腺癌MDA-MB-231细胞及其凋亡机制研究 . 药学实践与服务, 2017, 35(4): 337-340,358. doi: 10.3969/j.issn.1006-0111.2017.04.012
    [6] 夏涌, 黄健, 钱其军.  提高CAR-T细胞疗法抗癌活性及安全性的研究进展 . 药学实践与服务, 2016, 34(4): 372-376. doi: 10.3969/j.issn.1006-0111.2016.04.023
    [7] 姜文丽, 黄才国.  晚期非小细胞肺癌靶向治疗的研究进展 . 药学实践与服务, 2016, 34(4): 301-304,333. doi: 10.3969/j.issn.1006-0111.2016.04.004
    [8] 陈自强, 张玮, 李玉平, 王晓宇.  纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展 . 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
    [9] 王欢, 马志强, 杨峰.  用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展 . 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
    [10] 杨宏, 倪敏, 赵心彬, 陶霞.  辐射致组织损伤凋亡机制的研究概况 . 药学实践与服务, 2014, 32(2): 96-97,149. doi: 10.3969/j.issn.1006-0111.2014.02.005
    [11] 赵瑜, 姜华, 奚桂林, 李慧梁, 袁伯俊, 陆国才, 张卫东.  原藜芦碱A对大鼠心血管系统和呼吸系统的影响 . 药学实践与服务, 2010, 28(5): 348-351.
    [12] 章忱, 程康, 郭炜, 卫洪昌.  麝香保心丸对裸小鼠人结肠癌肝转移模型促血管新生因子及肿瘤生长的影响 . 药学实践与服务, 2007, (5): 295-296,302.
    [13] 庞晓军, 黄军章, 刘国勇, 李香乐.  肿瘤基因治疗研究进展 . 药学实践与服务, 2006, (1): 4-6.
    [14] 丁力, 丁家崇, 郭葆玉.  抗肿瘤药物新靶点半胱天冬酶-10 . 药学实践与服务, 2006, (2): 76-79.
    [15] 王洋, 郑唯强.  雌激素及三苯氧胺对MCF-7乳腺癌细胞BP1基因表达的影响 . 药学实践与服务, 2005, (4): @-@.
    [16] 王彦, 刁亚英, 姜远英.  ABC转运蛋白与肿瘤多药耐药 . 药学实践与服务, 2003, (1): 28-31.
    [17] 范开华, 刘子文, 夏俊.  血卟啉二乙二醇对消化道肿瘤的光动力疗效观察 . 药学实践与服务, 2001, (2): 76-76.
    [18] 蒙诚跃, 梁自乾, 王润秀, 张立明, 李德绘, 覃桂萍.  应用人重组生长激素治疗大面积烧伤疗效的观察 . 药学实践与服务, 2001, (6): 326-327.
    [19] 管孝鞠, 王治乔, 王爱平.  定量检测细胞凋亡的ELISA法 . 药学实践与服务, 2000, (1): 39-42.
    [20] 范开华, 温定量, 周明惠, 夏俊.  2,7,12,18-四甲基-3,8-二(1-甲氧乙基)-13,17-二(3-乙胺基丙基)卟啉衍生物的合成及其光敏活性 . 药学实践与服务, 1999, (6): 344-346.
  • 加载中
计量
  • 文章访问数:  2702
  • HTML全文浏览量:  250
  • PDF下载量:  370
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-07-14
  • 修回日期:  2011-12-05

真核延长因子eEF1A功能研究进展

doi: 10.3969/j.issn.1006-0111.2012.02.003

摘要: 真核延长因子(eEFs)是一类在蛋白质合成过程中发挥肽链延伸作用的重要分子,在真核生物体内它有eEF1和eEF2两个亚型。其中在肽链延伸过程中起主要作用的eEF1A 是eEF1的一个亚型,它不但能促进氨酰基-tRNA(aa-tRNA)与核糖体的A位点结合,发挥肽链延伸功能;而且近年来大量的研究表明它在细胞凋亡、肿瘤的发生、细胞内信号转导及心血管系统的调节方面均发挥了重要作用,而且这些作用与它在蛋白合成中的功能无关;这表明eEF1A是一个多功能蛋白,能够成为一个潜在的疾病防治的靶点。本文就国内外近几年来有关eEF1A的研究做一综述,介绍真核延长因子eEF1A功能研究的进展。

English Abstract

程君, 芮耀诚. 真核延长因子eEF1A功能研究进展[J]. 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
引用本文: 程君, 芮耀诚. 真核延长因子eEF1A功能研究进展[J]. 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
CHENG Jun, RUI Yao-cheng. Advance in function of the eukaryotic elongation factor eEF1A[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
Citation: CHENG Jun, RUI Yao-cheng. Advance in function of the eukaryotic elongation factor eEF1A[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
参考文献 (26)

目录

    /

    返回文章
    返回